HETEROCYCLES, Vol.55 No.3 pp.453 - 456 Received, 30th November, 2000

# ASYMMETRIC ALLYLIC ALKYLATION USING PLANAR CHIRAL PHOSPHINE-HYDRAZONE LIGANDS

Takashi Mino, [a]* Teruhiro Ogawa[b], and Masakazu Yamashita[b]

[a] Department of Materials Technology, Faculty of Engineering, Chiba University, Inage, Chiba 263-8522 Japan
[b] Department of Molecular Science and Technology, Faculty of Engineering, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan

***Abstract –*** Palladium-catalyzed asymmetric allylic substitution of 1,3-diphenyl-2-propenyl acetate (**3**) with a dimethyl malonate-BSA-lithium acetate system has been successfully carried out in the presence of chiral ferrocene hydrazone such as (*S*)-α-(diphenylphosphino)ferrocenecarboxaldehyde SAMP hydrazone (DPPFA-SAMP) ((*S*,*S*)-**2a**) in high yields with high enantioselectives (up to 96% ee).

Synthesis of chiral ferrocene derivatives has attracted much interest in various research fields.[1] Planar chiral ferrocenes have shown efficiency as catalysts for asymmetric synthesis. Palladium-catalyzed allylic substitution is a versatile and widely used process in organic synthesis,[2] and the development of an efficient enantioselective catalysis for this reaction is an important goal of current research in this area.[3] Recently, therefore, chiral ferrocene ligands with planar chirality have begun to be used in palladium-catalyzed allylic substitution.[4]

We previously described palladium-catalyzed asymmetric allylic substitution, using 2-diphenyl-phosphinobenzaldehyde SAMP hydrazone (DPPB-SAMP) (**1**) as a chiral ligand.[5] Here we report novel phosphine-hydrazone ligands (**2**) with planar chirality which give good results in asymmetric allylic substitution.




**1**




a : R = H, b = Me, c : R = Et

**2**

Phosphine-hydrazone ligands (**2**) can be easily prepared from (*S*)-α-(diphenylphosphino)ferrocene-carboxaldehyde[4c] with SAMP ((*S*)-1-amino-2-(methoxymethyl)pyrrolidine), SADP ((*S*)-amino-2-(1'-

methoxy-1'-methylethyl)pyrrolidine), SAEP ((*S*)-amino-2-(1'-methoxy-1'-ethylpropyl)pyrrolidine), and RAMP ((*R*)-1-amino-2-(methoxymethyl)pyrrolidine) which is enantiomer of SAMP in good yields.[6]

These ligands were examined in palladium-catalyzed asymmetric allylic alkylation of racemic 1,3-diphenyl-2-propenyl acetate (**3**)[7] with dimethyl malonate in the presence of *N*,*O*-bis(trimethylsilyl)acetamide (BSA)[8] at room temperature (Scheme 1, Table 1). Using SAMP hydrazone ((*S*,*S*)-**2a**) and lithium acetate in $CH_2Cl_2$ (Entry 1), product (**4**) was obtained in an 86% yield and 92% ee. When toluene was used instead of $CH_2Cl_2$, the enantioselectivity of **4** increased to 96% ee (Entry 4). When sodium acetate or potassium acetate was used instead of lithium acetate in toluene, the yield and/or enantioselectivity of **4** decreased (Entries 6 and 7 vs Entry 4). The optimized result was therefore obtained when the reaction was carried out in the presence of lithium acetate as a base in toluene.




**Scheme 1**

**Table 1.** Enantioselective Allylic Alkylation Catalyzed by Palladium Complexes with Chiral Hydrazone Ligands (**2**).[a]

| Entry | Ligand | Solv. | M | Yield of **4** / %[b] | Ee of **4** / %[c] | Config. of **4** |
|---|---|---|---|---|---|---|
| 1 | (*S*,*S*)-**2a** | $CH_2Cl_2$ | Li | 86 | 92 | *R* |
| 2 | (*S*,*S*)-**2a** | THF | LI | 88 | 92 | *R* |
| 3 | (*S*,*S*)-**2a** | MeCN | Li | 90 | 90 | *R* |
| 4 | (*S*,*S*)-**2a** | PhMe | Li | 93 | 96 | *R* |
| 5 | (*S*,*S*)-**2a** | $Et_2O$ | Li | 90 | 92 | *R* |
| 6 | (*S*,*S*)-**2a** | PhMe | Na | 87 | 95 | *R* |
| 7 | (*S*,*S*)-**2a** | PhMe | K | 82 | 89 | *R* |
| 8 | (*S*,*S*)-**2b** | PhMe | Li | 90 | 90 | *R* |
| 9 | (*S*,*S*)-**2c** | PhMe | Li | 88 | 74 | *R* |
| 10 | (*S*,*R*)-**2a** | PhMe | Li | 94 | 46 | *S* |

[a] Molar ratio : $[Pd(\eta^3\text{-}C_3H_5)Cl]_2$ (0.02 eq.), ligand (0.04 eq.), dimethyl malonate (3.0 eq.), BSA (3.0 eq.), MOAc (0.01 eq.).
[b] Isolated yields.
[c] The *ee* values were determed by HPLC analysis using a chiral column (Chiralcel OD (Hexane:*i*-PrOH=99:1)).

In this condition, SADP hydrazone ((*S*,*S*)-**2b**) and SAEP hydrazone ((*S*,*S*)-**2c**) were used instead of (*S*,*S*)-**2a**, and the enantioselectivity of **4** decreased (Entries 8 and 9 vs Entry 4). Product (**4**) was formed with the (*R*)-(+)-enantiomer predominating, as determined from the sign of the optical rotation.[9]

We next investigated the asymmetric allylic alkylation using the diastereomer of (*S*,*S*)-**2a** as ligand. The enantioselectivity of **4** decreased and the configuration of **4** was inverted using the ligand ((*S*,*R*)-**2a**)

which was prepared from (*S*)-α-(diphenylphosphino)ferrocenecarboxaldehyde and RAMP (Entry 4 vs Entry 10). This observation indicates that the central chirality in the hydrazone unit is more influential factor determining the stereochemical outcome in the allylic alkylation than the planar chirality.

In summary, this study has shown that phosphine-hydrazone ligands with planar chirality such as **2a** can be used in palladium-catalyzed asymmetric allylic alkylation with high enantiomeric excess.

## REFERENCES AND NOTES


1. For leading references, see; (a) *Ferrocenes*; ed. by A. Togni and T. Hayashi, VCH, Weinheim, 1995. (b) C. J. Richards and A. J. Locke, *Tetrahedron: Asymmetry*, 1998, **9**, 2377.
2. (a) J. Tsuji and I. Minami *Acc. Chem. Res.*, 1987, **20**, 140. (b) B. M. Trost and T. R. Verhoeven, in *Comprehensive Organometallic Chemistry*, ed. by G. Wilkinson, F. G. A. Stone, and E. W. Abel, Pergamon, Oxford, 1982, Vol. 8, p. 799. (c) B. M. Trost, *Acc. Chem. Res.*, 1980, **13**, 385.
3. (a) B. M. Trost and D. L. Van Vranken, *Chem. Rev.*, 1996, **96**, 395. (b) J. M. J. Williams, *Synlett*, 1996, 705. (c) A. Pfaltz, *Acc. Chem. Res.*, 1993, **26**, 339. (d) T. Hayashi, in *Catalytic Asymmetric Synthesis*; I. Ojima, Ed; VCH Publishers, New York, 1993. (e) G. Consiglio and R. M. Waymouth, *Chem. Rev.*, 1989, **89**, 257 and references cited therein.
4. For some recent papers on palladium catalyzed allylic substitution see; (a) W-P. Deng, X-L. Hou, L-X. Dai, L-X. Yu, and W. Xia, *Chem. Commun.*, 2000, 285. (b) S-L. You, X-L. Hou, and L-X. Dai, *Tetrahedron: Asymmetry*, 2000, **11**, 1495. (c) D. Enders, R. Peters, J. Runsink, and J. W. Bats, *Org. Lett.*, 1999, **1**, 1863. (d) W. Zhang, T. Shimanuki, T. Kida, Y. Nakatsuji, and I. Ikeda, *J. Org. Chem.*, 1999, **64**, 6247. (e) S-L. You, Y-G. Zhou, X-L. Hou, and L-X. Dai, *Chem. Commun.* 1998, 2765. (f) K. H. Ahn, C-W. Cho, J. Park, and S. Lee, *Bull. Korean Chem. Soc.*, 1997, **18**, 789. (g) O. Riant, O. Samuel, T. Flessner, S. Taudien, and H. B. Kagan, *J. Org. Chem.*, 1997, **62**, 6733.
5. T. Mino, W. Imiya and M. Yamashita, *Synlett*, 1997, 583.
6. **Typical Procedure for the Preparation of 2**. A mixture of (*S*)-α-(diphenylphosphino)-ferrocenecarboxaldehyde (0.38 mmol), chiral hydrazine (0.46 mmol), and benzene (10 mL) was heated at 100°C for 6 h under an argon atmosphere, and then cooled to room temperature. The reaction mixture was diluted with ether and water. The organic layer was washed with brine and dried over $MgSO_4$. The filtrate was concentrated with a rotary evaporator and the residue was purified by column chromatography.

   (*S*)-α-(Diphenylphosphino)ferrocenecarboxaldehyde SAMP hydrazone ((*S*,*S*)-**2a**): 99%; $[\alpha]^{D}_{25}$ = +138.0 ° (*c* 0.50, $CHCl_3$); $^1$H NMR (300 Mz, $CDCl_3$) δ 1.72–1.99 (m, 4H), 2.73 (dd, 8.0 and 16.8 Hz, 1H), 3.14–3.30 (m, 2H), 3.25 (s, 3H), 3.31–3.39 (m, 1H), 3.39–3.45 (m, 1H), 3.65–3.71 (m, 1H), 4.07 (s, 5H), 4.31 (t, 2.4 Hz, 1H), 4.75–4.86 (m, 1H), 7.13–7.25 (m, 6H), 7.32–7.43 (m, 3H), 7.48–7.48 (m, 2H); $^{13}$C NMR (75 Mz, $CDCl_3$) δ 21.98, 26.41, 49.41, 59.06, 63.01, 68.41 (d, 3.1 Hz), 69.79, 70.12, 72.05 (d, 3.8 Hz), 74.08, 74.36 (d, 10.0 Hz), 88.73 (d, 17.7 Hz), 127.50, 127.96 (d, 6.0

Hz), 128.08 (d, 7.7 Hz), 129.01, 131.50 (d, 7.0 Hz), 132.16 (d, 17.8 Hz), 135.26 (d, 21.1 Hz), 137.92 (d, 10.2 Hz), 140.33 (d, 11.1 Hz); $^{31}$P NMR (121 Mz, $CDCl_3$) δ -19.80; FAB-MS *m / z* 510 ($M^+$, 30); HRMS (FAB) calcd for $C_{29}H_{31}N_2OPFe$ ($M^+$) 510.1523, found 510.1499.

(*S*)-α-(Diphenylphosphino)ferrocenecarboxaldehyde SADP hydrazone ((*S*,*S*)-**2b**): 89%; $[\alpha]^D_{25}$ = +576.0 ° (*c* 0.50, $CHCl_3$); $^1$H NMR (400 Mz, $CDCl_3$) δ 1.11 (s, 3H), 1.17 (s, 3H), 1.77-1.98 (m, 4H), 2.63 (dd, 8.5 and 15.9 Hz, 1H), 3.22 (s, 3H), 3.40-3.49 (m, 2H), 3.71-3.72 (m, 1H), 4.04 (s, 5H), 4.33 (t, 2.4 Hz, 1H), 4.89-4.91 (m, 1H), 7.12-7.23 (m, 5H), 7.25 (s, 1H), 7.36-7.39 (m, 3H), 7.50-7.58 (m, 2H); $^{13}$C NMR (75 Mz, $CDCl_3$) δ 21.03, 23.07, 23.69, 24.64, 49.59, 51.12, 67.71 (d, 3.5 Hz), 69.96, 70.06, 71.17, 71.76 (d, 3.5 Hz), 74.31 (d, 9.4 Hz), 77.69, 89.09 (d, 18.5 Hz), 127.62, 128.06, 127.07 (d, 13.4 Hz), 129.08, 130.22 (d, 9.7 Hz), 132.16 (d, 17.7 Hz), 135.16 (d, 21.0 Hz), 137.53 (d, 9.4 Hz), 140.00 (d, 10.5 Hz); $^{31}$P NMR (121 Mz, $CDCl_3$) δ -20.84; FAB-MS *m / z* 538 ($M^+$, 38); HRMS (FAB) calcd for $C_{31}H_{35}N_2OPFe$ ($M^+$) 538.1836, found 538.1852.

(*S*)-α-(Diphenylphosphino)ferrocenecarboxaldehyde SAEP hydrazone ((*S*,*S*)-**2c**): 84%; $[\alpha]^D_{25}$ = +526.0 ° (*c* 0.50, $CHCl_3$); $^1$H NMR (400 Mz, $CDCl_3$) δ 0.88 (t, 7.5 Hz, 3H), 0.90 (t, 7.1 Hz, 3H), 1.42-2.05 (m, 8H), 2.64 (dd, 9.5 and 17.5 Hz, 1H), 3.26 (s, 3H), 3.33-3.42 (m, 1H), 3.64 (dd, 2.5 and 8.5 Hz, 1H), 3.71 (dt, 1.2 and 2.3 Hz, 1H), 4.03 (s, 5H), 4.33 (t, 2.5 Hz, 1H), 4.94 (dt, 1.2 and 2.3 Hz, 1H), 7.13-7.24 (m, 5H), 7.25 (s, 1H), 7.36-7.40 (m, 3H), 7.51-7.58 (m, 2H); $^{13}$C NMR (75 Mz, $CDCl_3$) δ 7.89, 8.62, 23.55, 23.69, 24.38, 26.25, 50.36, 50.66, 67.50 (d, 3.5 Hz), 69.97, 70.09, 70.34, 71.75 (d, 3.6 Hz), 74.19 (d, 9.2 Hz), 80.40, 89.22 (d, 18.6 Hz), 127.68, 128.09, 127.10 (d, 12.8 Hz), 129.05 (d, 9.9 Hz), 129.12, 132.15 (d, 17.6 Hz), 135.15 (d, 20.9 Hz), 137.44 (d, 9.2 Hz), 139.93 (d, 10.3 Hz); $^{31}$P NMR (121 Mz, $CDCl_3$) δ -20.99; FAB-MS *m / z* 566 ($M^+$, 22); HRMS (FAB) calcd for $C_{33}H_{39}N_2OPFe$ ($M^+$) 566.2150, found 566.2157.

(*S*)-α-(Diphenylphosphino)ferrocenecarboxaldehyde RAMP hydrazone ((*S*,*R*)-**2a**): 93%; $[\alpha]^D_{25}$ = +282.0 ° (*c* 0.50, $CHCl_3$); $^1$H NMR (400 Mz, $CDCl_3$) δ 1.71-2.05 (m, 4H), 2.84 (dd, 8.1 and 16.6 Hz, 1H), 3.21-3.41 (m, 3H), 3.33 (s, 3H), 3.54 (dd, 5.6 and 9.2 Hz, 1H), 3.71 (t, 1.1 Hz, 1H), 4.04 (s, 5H), 4.33 (t, 2.4 Hz, 1H), 4.87 (t, 1.0 Hz, 1H), 7.11-7.24 (m, 5H), 7.29 (s, 1H), 7.36-7.40 (m, 3H), 7.50-7.59 (m, 2H); $^{13}$C NMR (75 Mz, $CDCl_3$) δ 22.01, 26.58, 49.73, 59.15, 63.23, 68.76 (d, 3.2 Hz), 70.03, 70.24, 72.00 (d, 4.0 Hz), 74.36, 74.49, 88.60 (d, 18.3 Hz), 127.56, 127.92 (d, 5.8 Hz), 128.08 (d, 7.6 Hz), 129.04, 132.12 (d, 9.9 Hz), 132.17 (d, 17.6 Hz), 135.26 (d, 21.1 Hz), 137.81 (d, 9.9 Hz), 139.99 (d, 10.5 Hz); $^{31}$P NMR (121 Mz, $CDCl_3$) δ -20.99; FAB-MS *m / z* 510 ($M^+$, 61); HRMS (FAB) calcd for $C_{29}H_{31}N_2OPFe$ ($M^+$) 510.1523, found 510.1542.


7. P. R. Auburn, P. B. Mackenzie and B. Bosnich, *J. Am. Chem. Soc.*, 1985, **107**, 2033.
8. B. M. Trost and D. J. Murphy, *Organometallics*, 1985, **4**, 1143.
9. T. Hayashi, A. Yamamoto, T. Hagihara, and Y. Ito, *Tetrahedron Lett.*, 1986, **27**, 191.